Terms: = Ovarian cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
46 results:
1. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
2. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Lee JM; Annunziata CM; Hays JL; Cao L; Choyke P; Yu M; An D; Turkbey IB; Minasian LM; Steinberg SM; Chen H; Wright J; Kohn EC
Gynecol Oncol; 2020 Oct; 159(1):88-94. PubMed ID: 32747013
[TBL] [Abstract] [Full Text] [Related]
3. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Duska LR; Petroni GR; Varhegyi N; Brown J; Jelovac D; Moore KN; McGuire WP; Darus C; Barroilhet LM; Secord AA
Gynecol Oncol; 2020 Jun; 157(3):585-592. PubMed ID: 32247603
[TBL] [Abstract] [Full Text] [Related]
4. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Kaplan AR; Gueble SE; Liu Y; Oeck S; Kim H; Yun Z; Glazer PM
Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092693
[TBL] [Abstract] [Full Text] [Related]
5. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.
Liu Y; Chanana P; Davila JI; Hou X; Zanfagnin V; McGehee CD; Goode EL; Polley EC; Haluska P; Weroha SJ; Wang C
Sci Rep; 2019 Apr; 9(1):6314. PubMed ID: 31004097
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Characterization of Non-responders to Chemotherapy in Serous ovarian cancer.
McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
[TBL] [Abstract] [Full Text] [Related]
7. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract] [Full Text] [Related]
8. Nintedanib in ovarian cancer.
Khalique S; Banerjee S
Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
[TBL] [Abstract] [Full Text] [Related]
9. PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment.
Watts TL; Cui R; Szaniszlo P; Resto VA; Powell DW; Pinchuk IV
J Transl Med; 2016 Dec; 14(1):337. PubMed ID: 27931212
[TBL] [Abstract] [Full Text] [Related]
10. Perivascular pdgfr-β is an independent marker for prognosis in renal cell carcinoma.
Frödin M; Mezheyeuski A; Corvigno S; Harmenberg U; Sandström P; Egevad L; Johansson M; Östman A
Br J Cancer; 2017 Jan; 116(2):195-201. PubMed ID: 27931046
[TBL] [Abstract] [Full Text] [Related]
11. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women.
von Wolff M; Dittrich R; Liebenthron J; Nawroth F; Schüring AN; Bruckner T; Germeyer A
Reprod Biomed Online; 2015 Nov; 31(5):605-12. PubMed ID: 26380870
[TBL] [Abstract] [Full Text] [Related]
12. A pilot study of JI-101, an inhibitor of VEGFR-2, pdgfr-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.
Werner TL; Wade ML; Agarwal N; Boucher K; Patel J; Luebke A; Sharma S
Invest New Drugs; 2015 Dec; 33(6):1217-24. PubMed ID: 26365907
[TBL] [Abstract] [Full Text] [Related]
13. Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the treatment of Granulosa Cell Tumors of the Ovary.
Jamieson S; Fuller PJ
Int J Gynecol Cancer; 2015 Sep; 25(7):1224-31. PubMed ID: 26067856
[TBL] [Abstract] [Full Text] [Related]
14. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract] [Full Text] [Related]
15. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract] [Full Text] [Related]
16. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract] [Full Text] [Related]
17. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Mathey S; Graeser MK; Zu Eulenburg C; Woelber L; Trillsch F; Jaenicke F; Müller V; Milde-Langosch K; Mahner S
Oncology; 2013; 85(2):69-77. PubMed ID: 23860180
[TBL] [Abstract] [Full Text] [Related]
18. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
[TBL] [Abstract] [Full Text] [Related]
19. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
[TBL] [Abstract] [Full Text] [Related]
20. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
Jiao Y; Ou W; Meng F; Zhou H; Wang A
Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
[TBL] [Abstract] [Full Text] [Related]
[Next]
